WAVE Life Sciences Revenue and Competitors
Estimated Revenue & Valuation
- WAVE Life Sciences's estimated annual revenue is currently $79.9M per year.
- WAVE Life Sciences received $93.4M in venture funding in April 2017.
- WAVE Life Sciences's estimated revenue per employee is $217,000
- WAVE Life Sciences's total funding is $174M.
Employee Data
- WAVE Life Sciences has 368 Employees.
- WAVE Life Sciences grew their employee count by 8% last year.
WAVE Life Sciences's People
| Name | Title | Email/Phone |
|---|
WAVE Life Sciences Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5.2M | 67 | -45% | $107.3M | N/A |
#2 | $0.3M | 2 | 0% | N/A | N/A |
#3 | $5.1M | 33 | 6% | N/A | N/A |
#4 | $11.9M | 77 | -37% | $312.8M | N/A |
#5 | $0.9M | 6 | 0% | N/A | N/A |
#6 | $235M | 300 | -5% | $340.9M | N/A |
#7 | $45.9M | 237 | -7% | $7.6M | N/A |
#8 | $3.9M | 50 | 35% | N/A | N/A |
#9 | $5.4M | 35 | 3% | N/A | N/A |
#10 | $1.6M | 10 | 0% | N/A | N/A |
What Is WAVE Life Sciences?
Wave Life Sciences Ltd. (NASDAQ: WVE) is utilizing its innovative and proprietary synthetic chemistry drug development platform to design, develop and commercialize stereopure nucleic acid therapeutics that precisely target the underlying cause of rare genetic diseases, delivering new treatment options for patients. Given the unique versatility of its chemistry platform, Wave's pipeline spans multiple oligonucleotide modalities including antisense, exon-skipping and single-stranded RNAi.
keywords:Biotechnology,Healthcare,Pharmaceuticals
$174M
Total Funding
368
Number of Employees
$79.9M
Revenue (est)
8%
Employee Growth %
N/A
Valuation
N/A
Accelerator
WAVE Life Sciences News
Wave Life Sciences Ltd's score of 57 means that it ranks higher than 57% of stocks in the sector. In addition, its overall score of 9 ranks it...
Wave Life Sciences posted earnings of ($0.86) per share in the same quarter last year, which would suggest a positive year-over-year growth rate...
Wave Life Sciences (Nasdaq: WVE) is a clinical-stage genetic medicines company committed to delivering life-changing treatments for people...
Wave Life Sciences (NASDAQ:WVE) was downgraded by stock analysts at BidaskClub from a “hold” rating to a “sell” rating in a research note ...
06, 2019 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (WVE), a clinical-stage genetic medicines company committed to delivering ...
Other Companies in Cambridge
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $96.9M | 369 | 48% | N/A |
#2 | $57.7M | 372 | -23% | $170M |
#3 | $57.8M | 373 | -86% | N/A |
#4 | $153.2M | 377 | -3% | N/A |
#5 | $68.9M | 380 | N/A | N/A |
WAVE Life Sciences Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2015-02-03 | $18.0M | A | RA Capital Management LLC | Article |
| 2015-08-19 | $66.0M | B | Foresite Capital | Article |
| 2015-12-16 | $30.0M | Undisclosed | Teva | Article |
| 2017-04-13 | $93.4M | Undisclosed | Multiple | Article |